Jedd Wolchok

Jedd Wolchok

UNVERIFIED PROFILE

Are you Jedd Wolchok?   Register this Author

Register author
Jedd Wolchok

Jedd Wolchok

Publications by authors named "Jedd Wolchok"

Are you Jedd Wolchok?   Register this Author

100Publications

7211Reads

40Profile Views

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2019 Oct 28;381(16):1535-1546. Epub 2019 Sep 28.

From the Royal Marsden NHS Foundation Trust, London (J.L.), and the College of Medicine, Swansea University, Swansea (J.W.) - both in the United Kingdom; the Oncology Institute of Veneto IRCCS, Padua (V.C.-S.), the European Institute of Oncology, IRCCS, Milan (P.F.F.), Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples (P.A.A.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and the Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital, Siena (M.M.) - all in Italy; the University of Colorado Cancer Center, Aurora (R.G.); Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille Hôpital Timone, Marseille (J.-J.G.), and Université de Paris, INSERM Unité 976, Assistance Publique-Hôpitaux de Paris Dermatology and Centres d'Investigation Clinique, Saint Louis Hospital, Paris (C.L.) - both in France; the Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); the University of Michigan, Ann Arbor (C.D.L.); Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas (C.L.C.); the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Universitäts Spital, Zurich, Switzerland (R.D.); Cross Cancer Institute, Edmonton, AB (M.S.), and the Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Tasman Oncology Research, Southport, QLD (A.H.), the Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney, Sydney, NSW (M.S.C., G.V.L.), and the Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and the Peter MacCallum Cancer Centre, Melbourne, VIC (G.M.) - all in Australia; General University Hospital Gregorio Marañon and Centro de Investigación Biomédica en Red de Oncología, Madrid (I.M.-R.); the Netherlands Cancer Institute, Amsterdam (J.H.); the Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Leuven, Leuven, Belgium (P.S.); University of California San Diego Health-La Jolla Moores Cancer Center, La Jolla (G.A.D.); the Department of Oncology, Odense University Hospital, Odense, Denmark (L.B.); Bristol-Myers Squibb, Princeton, NJ (J.I.R., A.B., A.M.); Dana-Farber Cancer Institute, Boston (F.S.H.); and the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1910836DOI Listing
October 2019

Immunotherapy of Melanoma: Facts and Hopes.

Clin Cancer Res 2019 Sep 28;25(17):5191-5201. Epub 2019 Mar 28.

Yale University School of Medicine, New Haven, Connecticut.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-1550DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726509PMC
September 2019

Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?

Cancer Cell 2019 Sep;36(3):215-217

Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2019.08.009DOI Listing
September 2019

Selective inhibition of low-affinity memory CD8 T cells by corticosteroids.

J Exp Med 2019 Sep 19. Epub 2019 Sep 19.

Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20190738DOI Listing
September 2019

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade.

Cell 2019 Aug;178(4):933-948.e14

Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA; Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2019.07.019DOI Listing
August 2019

Prognostic value of baseline metabolic tumor volume measured on F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy.

Eur J Nucl Med Mol Imaging 2019 Apr 28;46(4):930-939. Epub 2018 Nov 28.

Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4211-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451667PMC
April 2019

Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer.

Cell Rep 2019 Apr;27(3):806-819.e5

Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medicine, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22111247193039
Publisher Site
http://dx.doi.org/10.1016/j.celrep.2019.03.066DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719696PMC
April 2019

Correction to: Strategies for Predicting Response to Checkpoint Inhibitors.

Curr Hematol Malig Rep 2019 Feb;14(1):62

Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-018-0488-0
Publisher Site
http://dx.doi.org/10.1007/s11899-018-0488-0DOI Listing
February 2019

Acquired resistance to immunotherapy in MMR-D pancreatic cancer.

J Immunother Cancer 2018 11 20;6(1):127. Epub 2018 Nov 20.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-018-0448-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247688PMC
November 2018

Putting the Immunologic Brakes on Cancer.

Authors:
Jedd Wolchok

Cell 2018 11;175(6):1452-1454

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2018.11.006DOI Listing
November 2018

Strategies for Predicting Response to Checkpoint Inhibitors.

Curr Hematol Malig Rep 2018 10;13(5):383-395

Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11899-018-0471-9
Publisher Site
http://dx.doi.org/10.1007/s11899-018-0471-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6719799PMC
October 2018

Refusing to TAP out: 16 new human TEIPPs identified.

J Exp Med 2018 09 21;215(9):2233-2234. Epub 2018 Aug 21.

Memorial Sloan Kettering Cancer Center, New York, NY

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20181512DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122966PMC
September 2018

The hallmarks of successful anticancer immunotherapy.

Sci Transl Med 2018 09;10(459)

Departamento de Biología Funcional, Área de Inmunología, Universidad de Oviedo, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33006 Oviedo, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aat7807DOI Listing
September 2018

Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma.

Cancer Discov 2018 07 17;8(7):822-835. Epub 2018 May 17.

Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-0099DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030433PMC
July 2018

Combination immunotherapy: a road map.

J Immunother Cancer 2017 21;5:16. Epub 2017 Feb 21.

Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Z-1503, New York, NY 10065 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0218-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319100PMC
June 2018

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

J Clin Oncol 2018 06 28;36(17):1668-1674. Epub 2017 Dec 28.

Caroline Robert, Gustave Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Adil Daud, University of California, San Francisco, San Francisco, CA; Jedd D. Wolchok, Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, NY; Anthony M. Joshua, The Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H Lee Moffitt Cancer Center, Tampa; Richard W. Joseph, Mayo Clinic Cancer Center-Florida, Jacksonville, FL; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, UPMC Hillman Cancer Center, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead; Melanoma Institute Australia, Wollstonecraft; and Macquarie University, MQ Health, Health Sciences Centre; Peter Hersey, University of Sydney, Sydney, New South Wales, Australia; Jin Zhang, James Anderson, Scott J. Diede, and Scot Ebbinghaus, Merck & Co., Inc., Kenilworth, NJ; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.6270
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.6270DOI Listing
June 2018

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2018 06 14;36(17):1714-1768. Epub 2018 Feb 14.

Julie R. Brahmer, Johns Hopkins Kimmel Cancer Center; Jennifer S. Mammen, Johns Hopkins University, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria; Alexander Spira, Virginia Cancer Specialists and US Oncology Research, Fairfax, VA; Bryan J. Schneider, University of Michigan Health System, Ann Arbor, MI; Michael B. Atkins, Georgetown Lombardi Comprehensive Cancer Center; Cristina A. Reichner, Georgetown University; Laura D. Porter, Colon Cancer Alliance; Washington, DC; Kelly J. Brassil, Aung Naing, Loretta J. Nastoupil, Maria E. Suarez-Almazor, and Yinghong Wang, MD Anderson Cancer Center, Houston, TX; Jeffrey M. Caterino, The Ohio State University Wexner Medical Center, Columbus, OH; Ian Chau, The Royal Marsden Hospital and Institute of Cancer Research, London and Surrey, United Kingdom; Marc S. Ernstoff and Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Bianca D. Santomasso and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center; Jeffrey S. Weber, New York University Langone Medical Center, New York, NY; Pamela Ginex, Oncology Nursing Society, Pittsburgh, PA; Jennifer M. Gardner, Seattle Cancer Care Alliance and University of Washington, Seattle, WA; Sigrun Hallmeyer, Oncology Specialists SC, Park Ridge, IL; Jennifer Holter Chakrabarty, University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; David F. McDermott, Beth Israel Deaconess Medical Center; Carole Seigel, Massachusetts General Hospital Cancer Center, Boston, MA; John A. Thompson, Seattle Cancer Care Alliance, University of Washington, and the Fred Hutchinson Cancer Research Center, Seattle, WA; and Tanyanika Phillips, CHRISTUS St Frances Cabrini Cancer Center, Alexandria, LA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481621PMC
June 2018

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.

J Clin Oncol 2018 06 28;36(17):1685-1694. Epub 2018 Feb 28.

Min Yuen Teo, Kenneth Seier, Irina Ostrovnaya, Ashley M. Regazzi, Brooke E. Kania, Meredith M. Moran, Catharine K. Cipolla, Mark J. Bluth, Joshua Chaim, Alexandra Snyder, Maria I. Carlo, Michael F. Berger, Samuel Funt, Jedd D. Wolchok, Margaret K. Callahan, and Jonathan E. Rosenberg, Memorial Sloan Kettering Cancer Center; and Hikmat Al-Ahmadie, David B. Solit, Gopa Iyer, and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.7740DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366295PMC
June 2018

Non-conventional Inhibitory CD4Foxp3PD-1 T Cells as a Biomarker of Immune Checkpoint Blockade Activity.

Cancer Cell 2018 06;33(6):1017-1032.e7

Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medicine, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.05.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6648657PMC
June 2018

Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.

Oncotarget 2018 Jun 19;9(47):28702-28716. Epub 2018 Jun 19.

Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.25614DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033351PMC
June 2018

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Cancer Cell 2018 05 12;33(5):843-852.e4. Epub 2018 Apr 12.

Department of Medicine, Memorial Sloan Kettering Cancer Center, 885 2(nd) Avenue, New York, NY 10017, USA; Weill Cornell School of Medicine, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108183012
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2018.03.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953836PMC
May 2018

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

N Engl J Med 2018 May 16;378(21):1976-1986. Epub 2018 Apr 16.

From the Bloomberg-Kimmel Institute for Cancer Immunotherapy and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore (P.M.F., K.N.S., V.A., T.R.C., M.Z., S.C.Y., S.B., R.J.B., J.N., K.A.M., F.V., H.G., J.Z., J.X.C., H.Y.C., J.-W.S., R.B.S., J.W., E.G., H.W., G.L.R., J.M.T., V.E.V., S.L.T., J.R.B., D.M.P.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine (J.E.C., M.D.H., D.R.J., M.J.V., N.R., Z.O., V.R., J.D.W., T.M.) and the Ludwig Collaborative (J.D.W., T.M.) - all in New York; the Parker Institute for Cancer Immunotherapy, San Francisco (J.D.W., T.M.); and Swim Across America Laboratory, Charlotte, NC (J.D.W., T.M.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1716078
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1716078DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223617PMC
May 2018

Introducing a New Series: Immunotherapy Facts and Hopes.

Clin Cancer Res 2018 04 23;24(8):1773-1774. Epub 2018 Feb 23.

Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-0408DOI Listing
April 2018

Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.

Mol Ther 2018 04 31;26(4):1008-1019. Epub 2018 Jan 31.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Swim Across America-Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymthe.2018.01.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079372PMC
April 2018

PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.

J Clin Invest 2018 04 5;128(4):1413-1428. Epub 2018 Mar 5.

Department of Medicine, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI98047DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873884PMC
April 2018

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.

Cancer Cell 2018 04;33(4):581-598

Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medicine, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.03.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896787PMC
April 2018

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

J Clin Oncol 2018 03 16;36(7):633-641. Epub 2018 Jan 16.

Hira Rizvi, Francisco Sanchez-Vega, Konnor La, Walid Chatila, Philip Jonsson, Darragh Halpenny, Andrew Plodkowski, Niamh Long, Jennifer L. Sauter, Natasha Rekhtman, Travis Hollmann, Ronglai Shen, Ai Ni, Kathryn C. Arbour, Taha Merghoub, Jedd Wolchok, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Nicholas D. Socci, Michael F. Berger, Barry S. Taylor, Ahmet Zehir, David B. Solit, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely, Nikolaus Schultz, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; Taha Merghoub, Jedd Wolchok, Alexandra Snyder, Jamie E. Chaft, Mark G. Kris, Charles M. Rudin, Gregory J. Riely, and Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Kurt A. Schalper, Yale School of Medicine, New Haven, CT; Justin F. Gainor, Massachusetts General Hospital, Boston, MA; and Alexandra Snyder, Adaptive Biotechnologies, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.3384DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075848PMC
March 2018

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.

J Clin Oncol 2018 03 17;36(9):850-858. Epub 2018 Jan 17.

F. Stephen Hodi and Mizuki Nishino, Dana-Farber Cancer Institute, Boston, MA; Marcus Ballinger, Benjamin Lyons, Chris McKenna, Ina Rhee, Gregg Fine, Nathan Winslow, and Daniel S. Chen, Genentech, South San Francisco, CA; Jean-Charles Soria, AstraZeneca, Gaithersburg, MD; Josep Tabernero, Universitat Autònoma de Barcelona, Barcelona, Spain; Thomas Powles, Queen Mary University of London, London, United Kingdom; David Smith, Compass Oncology, Vancouver, WA; Axel Hoos, GlaxoSmithKline, Collegeville, PA; Ulrich Beyer, Roche Innovation Center, Basel, Switzerland; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.1644DOI Listing
March 2018

Altered self: the not-so-neo-antigens.

Authors:
Jedd D Wolchok

Nat Rev Immunol 2018 03 5;18(3):152. Epub 2018 Feb 5.

Memorial Sloan Kettering Cancer Center (MSKCC), New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nri.2018.7DOI Listing
March 2018

Cancer immunotherapy using checkpoint blockade.

Science 2018 03 22;359(6382):1350-1355. Epub 2018 Mar 22.

Department of Medicine, Ludwig Center and Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.aar4060DOI Listing
March 2018

Validation of Anti-Mouse PDL-1 Goat Polyclonal Antibody Staining with Mouse PDL-1 In Situ Hybridization on Adjacent Sections of Cell Pellets and Mouse Tumors.

Methods Mol Biol 2017 ;1554:253-262

Molecular Cytology Core Facility, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box # 333, New York, NY, 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-6759-9_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751444PMC
February 2018

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.

J Clin Oncol 2018 02 17;36(4):391-398. Epub 2017 Oct 17.

Margaret K. Callahan, Michael A. Postow, Neil H. Segal, Alexander Lesokhin, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY; Harriet Kluger and Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, and Yale-New Haven Hospital, New Haven, CT; Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; John M. Kirkwood, University of Pittsburgh Medical Center, Pittsburgh, PA; and Suba Krishnan, Rafia Bhore, and Christine Horak, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.72.2850
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.72.2850DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946731PMC
February 2018

Shared cancer neoantigens: Making private matters public.

J Exp Med 2018 01 21;215(1):5-7. Epub 2017 Dec 21.

Memorial Sloan Kettering Cancer Center (MSKCC); Parker Institute for Cancer Immunotherapy; MSKCC Center for Cell Engineering; Weill Cornell Medical and Graduate Schools, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20172188DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748868PMC
January 2018

Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6cCD103 Monocytic Antigen-Presenting Cells in Tumors.

Immunity 2018 01;48(1):91-106.e6

Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA; Department of Pediatrics, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.immuni.2017.12.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005382PMC
January 2018

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.

J Clin Oncol 2017 Dec 25;35(34):3807-3814. Epub 2017 Aug 25.

Dirk Schadendorf, University Hospital Essen and the German Cancer Consortium, Essen, Germany; Jedd D. Wolchok and Michael A. Postow, Memorial Sloan Kettering Cancer Center; Michael A. Postow, Weill Cornell Medical College, New York, NY; F. Stephen Hodi, Dana-Farber Cancer Institute; David McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Vanna Chiarion-Sileni, Istituto Oncologico Veneto, Veneto, Italy; Rene Gonzalez, University of Colorado Denver, Aurora, CO; Piotr Rutkowski, Maria Skłodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Jean-Jacques Grob, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille Timone, Marseille; Caroline Robert, Gustave Roussy and Université Paris-Sud, Paris, France; C. Lance Cowey, Texas Oncology-Baylor Cancer Center, Dallas, TX; Christopher D. Lao, University of Michigan, Ann Arbor, MI; Jason Chesney, University of Louisville, Louisville, KY; Kenneth Grossmann, Huntsman Cancer Institute, Salt Lake City, UT; Dana Walker and Rafia Bhore, Bristol-Myers Squibb, Princeton, NJ; and James Larkin, Royal Marsden Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.2289DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791828PMC
December 2017

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

J Clin Oncol 2017 Dec 15;35(34):3815-3822. Epub 2017 Sep 15.

Mario Sznol, Yale Comprehensive Cancer Center, New Haven, CT; Pier Francesco Ferrucci, Istituto Europeo di Oncologia, Milan; Massimo Guidoboni, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; David Hogg, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Pascal Wolter, University Hospitals Leuven, Leuven, Belgium; Celeste Lebbé, Université Paris Diderot, Paris; Luc Thomas, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France; John M. Kirkwood, Hillman Cancer Center, Pittsburgh, PA; Jacob Schachter, Sheba Medical Center, Ramat Gan, Israel; Gregory A. Daniels, University of California San Diego, Moores Cancer Center, La Jolla, CA; Jessica Hassel, University Hospital, Heidelberg, Germany; Jonathan Cebon, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria; Winald Gerritsen, University of Queensland, St Lucia; Victoria Atkinson, Gallipoli Medical Research Foundation, Greenslopes; Victoria Atkinson, Princess Alexandra Hospital, Brisbane, Queensland, Australia; Winald Gerritsen, Radboud University Medical Center, Nijmegen, the Netherlands; John McCaffrey, Irish Clinical Oncology Research Group, Dublin; Derek Power, Irish Clinical Oncology Research Group, Cork, Ireland; Dana Walker, Rafia Bhore, and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; and Jedd D. Wolchok, Parker Institute and Ludwig Center at Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.72.1167DOI Listing
December 2017

Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2017 12;377(25):2503-2504

Royal Marsden NHS Foundation Trust, London, United Kingdom

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMc1714339
Publisher Site
http://dx.doi.org/10.1056/NEJMc1714339DOI Listing
December 2017

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2017 10 11;377(14):1345-1356. Epub 2017 Sep 11.

From the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W., M.A.P., M.K.C.); Oncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua (V.C.-S.), European Institute of Oncology, Milan (P.F.F.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; University of Colorado, Denver (R.G.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); Aix-Marseille University, Hôpital de la Timone, Marseille (J.-J.G.), and Assistance Publique-Hôpitaux de Paris, Dermatology and Centres d'Investigation Clinique, INSERM Unité 976, Hôpital Saint-Louis, Université Paris Diderot, Paris (C.L.) - both in France; Texas Oncology-Baylor Cancer Center, Dallas (C.L.C.); University of Michigan, Ann Arbor (C.D.L.); the College of Medicine, Swansea University, Swansea (J.W.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Cross Cancer Institute, Edmonton, AB (M.S.), and Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Universitäts Spital, Zurich, Switzerland (R.D.); Tasman Oncology Research, Southport Gold Coast, QLD (A.H.), Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney (M.S.C.), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and Peter MacCallum Cancer Centre (G.M.) and the Olivia Newton-John Cancer Research Institute, University of Melbourne (J.C.), Melbourne, VIC - all in Australia; Netherlands Cancer Institute, Amsterdam (J.H.); University Hospitals Leuven, KU Leuven, Leuven, Belgium (O.B.); General University Hospital Gregorio Marañón, Madrid (I.M.-R.); Northwestern University, Chicago (J.S.); Bristol-Myers Squibb, Princeton, NJ (D.W., L.R., R.B.); and the Dana-Farber Cancer Institute, Boston (F.S.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709684DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706778PMC
October 2017

Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment.

Sci Signal 2017 Aug 29;10(494). Epub 2017 Aug 29.

Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scisignal.aak9702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851440PMC
August 2017

Checkpoint inhibition and melanoma: Considerations in treating the older adult.

J Geriatr Oncol 2017 Jul 11;8(4):237-241. Epub 2017 May 11.

Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center 1275 York Ave., New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2017.04.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629004PMC
July 2017

Curbing Tregs' (Lack of) Enthusiasm.

Cell 2017 06;169(6):981-982

Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Ludwig Institute for Cancer Research, New York, NY 10065, USA; Parker Institute for Cancer Immunotherapy, New York, NY 10065, USA; Weill Cornell Medicine, Cornell University, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2017.05.027DOI Listing
June 2017

Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab.

J Natl Cancer Inst 2017 04 31;109(4). Epub 2016 Dec 31.

Affiliations of authors: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY (CFF, VC, TB, ANS, PM, MKC, JDW, PBC, MDH, MAP); Weill Cornell Medical College, New York, NY (CFF, AVR, ANS, PM, MKC, JDW, PBC, MDH, MAP).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw260DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441295PMC
April 2017

Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.

Nat Rev Endocrinol 2017 04 20;13(4):195-207. Epub 2017 Jan 20.

Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, 10065 New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrendo.2016.205DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629093PMC
April 2017

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.

EBioMedicine 2017 Apr 24;18:56-61. Epub 2017 Mar 24.

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Weill Cornell Medical College, New York, NY, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2017.03.029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405176PMC
April 2017

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

J Clin Oncol 2017 Mar 14;35(7):785-792. Epub 2016 Nov 14.

Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Suzanne L. Topalian, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Hewei Li, Ian M. Waxman, and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ; Dirk Schadendorf, University of Essen, Essen, Germany; James Larkin, Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Georgina V. Long, Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia; and Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif-Paris Sud, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.1389DOI Listing
March 2017

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.

J Clin Oncol 2017 Jan 7;35(2):226-235. Epub 2016 Nov 7.

Sandra P. D'Angelo, Alexander N. Shoushtari, and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; James Larkin, Royal Marsden Hospital, London; Paul Lorigan, University of Manchester, Manchester, United Kingdom; Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; Celeste Lebbé, Saint-Louis Hospital, Institut National de la Santé et de la Recherche Médicale U976, Université Paris Diderot, Paris; Julie Charles, Grenoble University Hospital, Grenoble Alps University, Grenoble, France; Benjamin Brady, Cabrini Health, Melbourne, Australia; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; Henrik Schmidt, Århus University, Åarhus, Denmark; Jessica C. Hassel, University Hospital Heidelberg, Heidelberg; Peter Mohr, Elbe Kliniken Buxtehude, Buxtehude; Martin Kaatz, SRH Waldklinikum Gera, University Hospital Jena, Jena, Germany; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Kerry J. Savage, BC Cancer Agency, University of British Columbia, Vancouver; Wilson H. Miller Jr, Lady Davis Institute and Jewish General Hospital, McGill University, Montreal, Canada; Ivan Marquez-Rodas, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Jeffrey S. Weber, Moffitt Cancer Center, Tampa, FL; and Mary Ruisi and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.67.9258
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.67.9258DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559888PMC
January 2017

In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide.

Sci Immunol 2016 Jul 23;1(1):aaf6925. Epub 2016 Jun 23.

Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/sciimmunol.aaf6925DOI Listing
July 2016